Most ampicillin-resistant Shigella are susceptible to cephalexin. Randomized treatment with cephalexin or ampicillin was given to 154 infants and children with acute diarrhea. Rectal swab cultures revealed Shigella in 42%, Salmonella in 6%, enteropathogenic Escherichia coli in 2%, and no pathogen in 50%. Cephalexin failed to eradicate Shigella after 5 days of treatment in 76% of patients as contrasted with 28% of ampicillin-treated patients with susceptible organisms. Shigella persisted in 78% of ampicillin-treated patients with resistant organisms. Diarrhea lasted more than 5 days in 43% of cephalexin-treated patients, in 56% of the ampicillin group with resistant organisms, but in only 9% of ampicillintreated patients with susceptible organisms. The failure of cephalexin was due to the relatively high minimal inhibitory concentrations and minimal bacterial concentrations of 5 or 10 ug/ml and, although serum concentrations were twice the minimal bacterial concentration, they were not sufficient to demonstrate killing by the serum dilution method. In vitro susceptibility or resistance of Shigella to ampicillin correlated with clinical success or failure. Cephalexin is not a suitable drug for treatment of shigellosis in patients with ampicillin-resistant organisms.
Considering the rapidly increasing problem with ampicillin resistance of Shigella sonnei strains in the United States (2) it becomes important to look for suitable alternative drugs for treatment of severe shigellosis. Shigella strains that are multiply resistant to sulfas, tetracycline, chloramphenicol, and ampicillin generally retain their in vitro susceptibility to cephalosporin derivatives. In a previous study (5) we found that only one of 160 shigella strains was resistant to cephalothin, cephaloridine, cephaloglycin, and cephalexin. Cephaloglycin proved ineffective for shigellosis, presumably on the basis of the poor absorption, with most patients having no measurable levels of cephaloglycin in their blood. It therefore seemed worthwhile to carry out a clinical trial with cephalexin, which has much better absorption than cephaloglycin and quite consistently gives peak serum levels over 10 jig/ml with the recommended dosages.
MATERIALS AND METHODS
This study was done in the outpatient clinic of Children's Medical Center in Dallas and the protocol was essentially the same as in our previous study of ambulatory patients with diarrhea comparing am- ' Died 21 December 1973. picillin and placebo (3) . Infants and children with acute diarrhea were enrolled in the study at the initial clinic visit. Patients with respiratory infections or other possible causes of nonspecific diarrhea were excluded. They were assigned from random numbers lists to treatment either with cephalexin in a daily dosage of 80 mg/kg or with ampicillin in a daily dosage of 100 mg/kg. Both drugs were given in four divided doses for 5 days. When more than one child in a family was studied, all received the same drug to avoid possible confusion of medications.
Rectal swab cultures were examined by standard bacteriological methods (1) by using eosin-methylene blue agar, xylose-lysine-desoxycholate agar, tergitol-7 with tetrazolium chloride, and enrichment in tetrathionate broth (with 1:100,000 brilliant green and 2% iodine solution) for subculture to brilliant green agar.
Shigella and Salmonella isolates were submitted to the Texas State Department of Health Laboratory for confirmation and serotyping.
In vitro susceptibility testing of pathogens was performed by the broth dilution method using ampicillin and cephalexin laboratory standards. The inoculum was 10" bacteria. Twofold dilutions of antibiotic from 1,280 ,g/ml to 0.3 ug/ml were made in sensitivity test broth. After incubation at 37 C for 18 h the minimal inhibitory concentration was noted and tubes without visible turbidity were subcultured to 5% sheep's blood agar to determine the minimal bactericidal concentration.
Measurements of cephalexin or ampicillin in serum 416 NELSON AND HALTALIN were performed by the micromethod of Simon and Yin (7) using finger-stick blood.
Serum inhibitory and bactericidal titers were done using twofold dilutions of serum in brain-heart infusion broth. The Shigella strain isolated from the patient was inoculated into each well in a microtiter plate (105 bacteria) and the cultures were incubated for 18 h at 37 C. Clear wells were subcultured to 5% sheep's blood agar to determine the bactericidal titer.
Written, informed consent was obtained from parents.
Patients retumed for follow-up on days 2 or 3 and days 4 spectively, the average ages were 3.0, 3.3, and 2.5 years, the average durations of illness before therapy were 5.1, 3.4, and 3.5 days, and the average numbers of stools in the 24 h before starting treatment were 6.3, 6.2, and 7.1.
In selected patients serum concentrations of cephalexin and ampicillin were measured at the time of the initial visit (Table 3 ). The first dose of medication was given by the research nurse and serum specimens were collected 1 or 2 h later. An attempt was made to get sequential serum specimens for antibiotic assay by having the mothers remain in the clinic with the children for 4 h, but only a small number of patients cooperated. The peak serum level occurred after 0.5 to 1 h with both drugs. The mean peak concentration of ampicillin was approximately one-fourth that of cephalexin, and the range of values was much greater for ampicillin. The marked variability of ampicillin absorption in patients with shigellosis has been documented by us previously (6) .
All Shigella strains from cephalexin-treated patients were susceptible in vitro to cephalexin (Fig. 1) . Most (82%) were inhibited by 5 ,ug/ml or less but only 22% were killed at that concentration. All were killed at levels of 10 jug/ml.
Nine strains from the 36 ampicillin-treated patients (25%) were resistant in vitro to ampicillin. The resistant strains in this group were Diarrhea persisted longer than 5 days in approximately half of the shigellosis patients treated with cephalexin or those treated with ampicillin who had resistant organisms but in only 9% of the ampicillin-treated patients with susceptible organisms (Table 4 ). The average number of days after start of treatment until the diarrhea stopped was approximately twice as long in the cephalexin and ampicillin-resistant groups as in the ampicillin-treated patients with susceptible organisms. The average number of stools recorded by the mother was from 3.5 to 5.5 for the cephalexin-and ampicillinresistant groups. After only 24 h of treatment the number of stools was reduced below three in the ampicillin group of patients with susceptible organisms.
Serum inhibition titers against the Shigella strain isolated from each patient are correlated with the measured antibiotic serum concentration in Fig. 3 . In specimens from cephalexintreated patients, with one exception, inhibition was demonstrated only at serum concentrations greater than 10 gg/ml, but of the total 20 specimens with concentrations greater than 10 ,ug/ml, only 7 (35%) demonstrated inhibition.
By contrast, serum specimens with ampicillin concentrations of 2.5 ,ug/ml or greater were inhibitory to Shigella when the organisms were susceptible in vitro to less than 5 ,ug/ml with the exception of two patients with levels of 2.7 and (Fig. 4) . In The bacteriological and clinical responses of patients with shigellosis were analyzed by the chi-square test. Differences in frequency of positive rectal swab cultures on days 2 to 3 were significant between the ampicillin-susceptible group and the cephalexin group (P < 0.0005) and the ampicillin-resistant group (P < 0.0005), but not between the cephalexin group and the ampicillin-resistant group (P < 0.30). On days 4 to 6 the results were P < 0.005, P < 0.01, and P < 0.90, respectively, for the three comparisons. Differences between groups at the 10-to 20-day and later follow-ups were not statistically significant (P < 0.30 to P < 0.90). Persistence of diarrhea after 5 days treatment was significantly different between the ampicillin-susceptible group and cephalexin group (P < 0.005) and the ampicillin-resistant group (P < 0.005) but not between the cephalexin group and the ampicillin-resistant group (P < 0.40).
There were very few patients with Salmonella or enteropathogenic E. coli disease (Table 5 ). In the 11 patients with Salmonella the stool cultures of most remained positive during therapy with cephalexin or with ampicillin. Seven of the 11 patients still had positive cultures after 10 to 20 days. Only four were followed up longer than 21 days, and two of these remained positive. All five patients with enteropathogenic E. coli had negative cultures at the end of treatment. Salmonella patients treated with ampicillin had diarrhea persisting for an average of 5 days (range of 2 to 7 days) and of those treated with cephalexin it lasted for an average of 4.6 days (range of 3 to 6 days).
Of the patients without recognized pathogens at the beginning of treatment, 20% of those who received ampicillin and 11% of those who were treated with cephalexin still had diarrhea after 5 days of treatment. In the previous outpatient study (3) most patients with shigellosis in this study appears to be due to the fact that sufficient concentrations in serum are not achieved. Shigella are not resistant to cephalexin by the usual standards of susceptibility and resistance but the minimal inhibitory and bactericidal concentrations of 5 or 10 gg/ml are relatively high.
Although the mean peak serum concentration measured in these patients was almost 20 ug/ml and no patient had a peak level below 10 ,g/ml, this concentration of cephalexin appears insufficient to inhibit and kill Shigella organisms by the serum dilution technique. This is further substantiated by the observation that the few patients treated with cephalexin who had negative cultures during treatment were the same few who demonstrated serum bactericidal titers in vitro. This explanation of the failure of cephalexin is consistent with our previous conclusions that the most important determinant of success in treating shigellosis is attainment of effective serum, and presumably tissue, concentrations of antibiotic. The extreme variability of serum concentrations after orally administered ampicillin was once again documented in this study. This had previously been shown in hospitalized children with more severe shigellosis (6) and the children with poor absorption maintain positive stool cultures and have persistent diarrhea longer than those who achieve higher serum levels of ampicillin (4) . Undoubtedly this variable absorption of ampicillin accounts for some therapeutic failures in patients with shigellosis due to ampicillin-susceptible organisms.
We have not previously been able to treat a large enough group of patients with ampicillinresistant organisms with ampicillin to prove that therapeutic success or failure correlates with in vitro susceptibility or resistance but the differences were statistically significant in this study.
VOL. 7, 1975 on August 29, 2017 by guest http://aac.asm.org/ It is concluded that cephalexin is not a suitable alternative drug for treatment of shigellosis in patients with ampicillin. Presumably, if the drug were given in a larger dosage, effective suppression of Shigella would result. The manufacturer's recommended dosage is 25 to 50 mg/kg per day and it is doubtful that patients would tolerate dosages much larger than the 80 mg/kg per day used in this study.
